Contact
Header_1077x260px_About_Profil.jpg

Glucose-Infusion-Rate based categorization of glucose clamps

The glucose clamp is a method for the determination of pharmacokinetic and pharmacodynamic (PK/PD) effects of anti-diabetic drugs (e.g. insulin) where the blood glucose (BG) concentration lowering effect is antagonized by variable glucose infusion rates (GIR).

Read More

Topics: Clinical Trials in Diabetes, Diabetes Technology

Posted by Mareike Kuhlenkötter on Jan 15, 2019 5:03:00 PM

Update on Brexit: Impact on future and current clinical trials in Germany

As the withdrawal of the United Kingdom from the European Union is coming closer, the Competent Authority in Germany (BfArM) recently published their procedures for the period thereafter.

Read More

Topics: Clinical Trials in Diabetes

Posted by Dr. Grit Andersen on Jan 8, 2019 5:05:00 PM
dr-grit-andersen

Happy new year 2019

2018 is over -  and the Profil blog has seen many interesting articles through the last months. We have posted about conferences, webinars and scientific topics for clinical diabetes researchers. 

We are happy to see that many readers are interested in our blog posts. Our most popular blogs deal with the error grid analysis, improvements of insulin injections and diabetic and hepatic encephalopathyWe are very pleased that the Profil blog has found so many readers again last year and we will continue to bring the most interesting topics to you also in 2019.

Read More

Topics: About Profil

Posted by Svenya Meister on Jan 3, 2019 5:23:00 PM
svenya-meister

Pramlintide as adjunct therapy for the treatment of type 1 diabetes

Where are we today?

Insulin treatment for type 1 diabetes mellitus (T1D) has improved over the past decades due to advances in insulin formulations and administration techniques. Nevertheless, optimal glucose control and reaching HbA1c goals remain challenging for many patients. Consequently, the risk of subsequent micro- and macrovascular complications remains high and life expectancy is still reduced in this patient group so that there is an obvious need for improvement of current therapies or the development of new, additional treatments [1]. So what else can be done?

 

Read More

Topics: Treating Diabetes, Clinical Trials in Diabetes

Posted by Dr. Susanne Famulla on Dec 19, 2018 5:12:00 PM
dr-susanne-famulla

Obesity treatment with lorcaserin

New data on metabolic & cardiovascular safety and efficacy

Worldwide, the incidence of obesity is increasing dramatically having almost tripled in the last 40 years [1]. In 2016, 39% of adults aged 18 years and older were overweight - 13% were obese. Because obesity is associated with an array of metabolic pathologies, including cardiovascular disease, type 2 diabetes, musculoskeletal disorders, and even some cancers, identifying effective strategies for sustained weight loss are imperative.

Read More

Topics: Clinical trials in Obesity

Posted by Dr. Daniela Lamers on Dec 11, 2018 5:21:00 PM
dr-daniela-lamers

New data on cardiovascular outcomes with dapagliflozin

Putting effects of SGLT2 inhibitors into perspective

The DECLARE-TIMI 58 trial [1] investigated the effects of treatment with dapagliflozin on cardiovascular outcomes in people with type 2 diabetes in a double blind randomized placebo controlled manner. It is the third published trial investigating cardiovascular outcomes of SGLT2 inhibitors, following EMPA-REG (for empagliflozin) [2] in 2015 and CANVAS (canagliflozin) [3] in 2017. Of these three trials, DECLARE-TIMI 58 has been the largest by a fair margin, including more than 17000 patients with type 2 diabetes who either had multiple risk factors for atherosclerotic cardiovascular disease or established cardiovascular disease.

Read More

Topics: Clinical Trial Methods, Clinical Trials in Diabetes, The Science behind Diabetes

Posted by Oliver Klein on Dec 4, 2018 5:09:00 PM
oliver-klein

Glucose-Responsive Insulin

The first idea [1] for a glucose-responsive insulin (GRI, commonly referred to as smart insulin) was pitched almost 40 years ago, but to our knowledge only one compound has since undergone clinical evaluation. It seems a little surprising that it takes such a long time to develop a functioning GRI because its concept is actually relatively simple: At normal glucose concentrations, small amounts of insulin are released to keep blood glucose (BG) fairly constant. In response to rising glucose concentrations, for example after a meal, more insulin is released to limit the glucose rise and to return glucose concentrations back to normal. This closed-loop insulin release should limit BG variability and because insulin is only released when it is needed, it should also reduce the risk of over- and underdosing insulin. Two key elements are needed for a GRI: (1) A component that can ‘sense’ glucose and (2) a component that can respond and control the release of insulin. The concept may be simple, suggested solutions are complex and diverse [2].

Read More

Topics: Diabetes Technology, Clinical Trial Methods, Clinical Trials in Diabetes

Posted by Dr. Eric Zijlstra on Nov 28, 2018 5:19:00 PM
dr-eric-zijlstra

New strategies for the treatment of obesity and metabolic dysfunctions

Targeting the incretin/glucagon system with agonists

Figure 1: Schematic representation of the effects of multi-agonists targeting the receptors for GLP-1/Glucagon, GLP-1/GIP and GLP-1/GIP/Glucagon [28]

In Part I of our blog we reported on dual receptor agonists targeting the incretin/glucagon system to treat obesity and type 2 diabetes mellitus with high efficacy. So far, it has been recognized that the concept of combined targeting of gut hormone receptors is also working in humans [1, 2]. In Part II we will focus on the twincretins GIP and GLP-1 [3] to improve glycaemic control and the tri-agonists GLP-1/GIP/Glucagon to treat obesity, type 2 diabetes mellitus and hepatosteatosis [non-alcoholic steatohepatitis (NASH)].

Read More

Topics: Treating Diabetes

Posted by Dr. Ulrike Hövelmann on Nov 13, 2018 5:09:00 PM
dr-ulrike-hövelmann

What news in the treatment of Type 2 diabetes was presented at EASD 2018?

The annual meeting of the European Association for the Study of Diabetes (EASD) took place this year in Berlin, Germany. The present text offers a selection of topics relevant for the field of type 2 diabetes mellitus (T2DM) discussed during that meeting.

Read More

Topics: The Science behind Diabetes, Diabetes Technology, Clinical Trial Methods

Posted by Dr. Jorge Arrubla on Nov 6, 2018 5:09:00 PM
dr-jorge-arrubla

Profil at 18th Annual Diabetes Technology Meeting

Profil will be present at the 18th Annual Diabetes Technology Meeting with two posters and a presentation as invited speaker. The Annual DTM will take place from November 8 to November 10, 2018, in North Bethesda, Maryland. We are looking forward to this exciting event.

Read More

Topics: The Science behind Diabetes, Diabetes Technology, Clinical Trial Methods

Posted by Svenya Meister on Oct 29, 2018 5:15:00 PM
svenya-meister

Subscribe to our monthly blog updates

New Call-to-action

Subscribe to Email Updates

Our most popular Posts